3-[6-[[4-(三氟甲氧基)苯基]氨基]-4-嘧啶基]苯甲酰胺
![3-[6-[[4-(三氟甲氧基)苯基]氨基]-4-嘧啶基]苯甲酰胺结构式](https://image.chemsrc.com/caspic/277/778270-11-4.png)
3-[6-[[4-(三氟甲氧基)苯基]氨基]-4-嘧啶基]苯甲酰胺结构式
|
常用名 | 3-[6-[[4-(三氟甲氧基)苯基]氨基]-4-嘧啶基]苯甲酰胺 | 英文名 | GNF-2 |
|---|---|---|---|---|
| CAS号 | 778270-11-4 | 分子量 | 374.317 | |
| 密度 | 1.4±0.1 g/cm3 | 沸点 | 536.4±50.0 °C at 760 mmHg | |
| 分子式 | C18H13F3N4O2 | 熔点 | N/A | |
| MSDS | 中文版 美版 | 闪点 | 278.2±30.1 °C | |
| 符号 |
GHS07 |
信号词 | Warning |
|
Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
Nat. Chem. Biol. 2 , 95-102, (2006) Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized at the molecular level by the expression of Bcr-abl, a 210-kDa fusion protein with deregulated tyrosine kinase activity. Encouraged by the clinical validation of Bcr-abl as the ... |
|
|
Inhibitors of Bcr-abl... breaking new ground again.
Nat. Chem. Biol. 2nd ed.,, 63-64, (2006)
|
期刊文献综述：
更多...